Andras Attila Heczey

Andras Attila Heczey, M.D.

Associate Professor

Email

heczey@bcm.edu

Positions

Associate Professor: Pediatrics-Oncology
��Ƶ of Medicine
Houston, TX, US

Member: Dan L Duncan Comprehensive Cancer Center
��Ƶ of Medicine
Houston, Texas, United States

Addresses

Texas Children's Hospital, Clinical Care Center (Clinic): 6701 Fannin St., 14th floor
Houston, TX, 77030
United States
Phone: (832) 822-4242

Education

Fellowship at ��Ƶ Of Medicine Affiliate Hospitals: 01/2012 - Houston, TX, United States

Residency at Children's Hospital Of Los Angeles: 01/2009 - Los Angeles, CA, United States

M.D. from Semmelweis Medical University: 09/2002 - Budapest, Budapest, Hungary

Certifications

General Pediatrics: American Board of Pediatrics

Pediatric Hematology and Oncology: American Board of Pediatrics

Professional Interests

Tumor immunotherapy
Genetic engineering

Professional Statement

Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of ��Ƶ of Medicine, Section of Pediatric Hematology and Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).

His research focuses on developing novel treatments for patients with solid tumors by redirecting the immune system to attack cancer cells.

Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma. This approach is tested in the GINAKIT2 Phase 1 clinical trial in children with relapsed or refractory high-risk neuroblastoma.
https://clinicaltrials.gov/ct2/show/NCT03294954

As the Director of the Liver Tumor Center, Dr. Heczey has developed unique strategies to target hepatoblastoma and hepatocellular carcinoma with genetically engineered T lymphocytes. This approach was successfully broadened to other solid cancers (in adults and children)

Active projects in the lab focus on synthetic immunology to successfully reprogram the immunesystem to recognize and completely eliminate cancer cells.
The Heczey Lab's ultimate goal is to develop new genetic engineering strategies to reprogram cells inside the human body, in situ.

Websites

Videos

Selected Publications

Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, Dotti G, Metelitsa LS. " " J. Clin. Invest.. 2012 Jun 1; 122 (6) : 2221-33.
Pubmed PMID: .
" ;
Pubmed PMID: .
Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, Liu H, Dotti G, Metelitsa LS. " " Blood. ;
Pubmed PMID: .
Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. " " Mol Ther. 2017 Jun 8;
Pubmed PMID: .
Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A1. " " Hum Gene Ther. 2017 May 28;
Pubmed PMID: .
Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS, Heczey A.. " " Canc Imm Res. 2020 Jan 17;
Pubmed PMID: .
Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, Savoldo B, Dotti G, Metelitsa LS5. " " Clin Canc Res. 2019 Dec 1;
Pubmed PMID: .
Heczey A. " " 2019 Aug 7;
Pubmed PMID: .
Haines K, Sarabia SF, Alvarez KR, Tomlinson G, Vasudevan S, Heczey A, Roy A, Finegold MJ, Parsons DW, Plon SE, López-Terrada D. " " Pediatr Blood Cancer. 2019 Jul ;
Pubmed PMID: .
Sumazin P, Chen Y, Treviño LR, Sarabia SF, Hampton OA, Patel K, Mistretta TA, Zorman B, Thompson P, Heczey A, Comerford S, Wheeler DA, Chintagumpala M, Meyers R, Rakheja D, Finegold MJ, Tomlinson G, Parsons DW, López-Terrada D. " " Hepatology. 2017 Jan ;
Pubmed PMID: .

Memberships

American Society of Clinical Oncology

Children's Oncology Group

American Society of Cell and Gene Therapy

AACR

Funding

Interleukin-15 and -21 armored Glypican-3-specific CAR T cells for patients with hepatocellular carcinoma: (04/01/2019 - 03/01/2025); Grant funding from Cancer Prevention and Research Institute of Texas

IL15 and IL21 armored GPC3-CAR T cells for children with solid tumors #R01CA258866: (01/01/2022 - 12/31/2026); Grant funding from National Institute of Health

Synthetic gene expression regulatory switches (SynGERS) expressed in CAR T cells to cure children with solid tumors: (02/01/2024 - 01/31/2028); Grant funding from ALSF

Cellular Immunotherapies for Pediatric Solid Tumors: (08/31/2024 - 08/30/2028); CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

Overcoming major barriers to the delivery of successful T-Cell Immunotherapies: (08/31/2024 - 08/30/2028); CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

Intellectual Property

: Design Patent #WO2016049459A1 (Pending)

: Design Patent #US20140255363A1 (Pending)

: Design Patent (Pending)

Languages

Hungarian

to edit your profile

������Ƶ